Malignant Glioma Clinical Trial
— PRiMEOfficial title:
The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Verified date | May 2024 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | April 2025 |
Est. primary completion date | April 27, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 35 Years |
Eligibility | Inclusion Criteria: 1. Patients who are 3 - 35 years old 2. Histopathologically proven previous diagnosis of medulloblastoma or Grade III or IV glioma. 3. Radiology evidence of recurrent medulloblastoma (reMB) or recurrent Grade III and IV glioma. Patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist. 4. Brain MRI within one month prior to enrollment. 5. Received prior therapy for their initial diagnosis prior to recurrence/progression or who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin's syndrome or NF1 mutation). 6. Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registration. 7. Karnofsky Performance Status (KPS) of = 60% (KPS for > 10 years of age) or Lansky performance Score (LPS) of = 60 (LPS for = 10 years of age) assessed within 2 weeks prior to registration. Patients who are unable to walk because of paralysis but who are up in a wheel chair will be considered ambulatory for the purposes of the performance score. 8. Bone Marrow: - ANC (Absolute neutrophil count) = 1000/µl (unsupported)*. - Platelets = 100,000/µl (unsupported)*. - Hemoglobin > 8 g/dL (may be supported). 9. Renal: • Serum creatinine = upper limit of institutional normal. 10. Hepatic: - Bilirubin = 1.5 times upper limit of normal for age. - SGPT (ALT) = 3 times institutional upper limit of normal for age. - SGOT (AST) = 3 times institutional upper limit of normal for age. 11. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study. 12. Signed informed consent according to institutional guidelines must be obtained prior to registration. 13. Any prior chemoradiotherapy is allowed. Exclusion Criteria: 1. Pregnant or need to breast feed during the study period (Negative serum pregnancy test required). 2. Active infection requiring treatment or an unexplained febrile (> 101.5 degrees F) illness. 3. Known immunosuppressive disease or human immunodeficiency virus infection. 4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease. 5. Patients receiving concomitant immunosuppressive agents for medical condition. 6. Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent Grade III or IV glioma. 7. Patients receiving any other investigational drug therapy. 8. Patients on corticosteroids > 0.1 mg/Kg/day (i.e. > the maximum dose of 4 mg/day). 9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction). 10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy. |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Daniel Landi | Annias Immunotherapeutics, Inc., Pediatric Brain Tumor Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with unacceptable toxicity | Evaluate the safety of PEP-CMV in pediatric patients with recurrent MB or recurrent Grade III/IV glioma | 2 weeks after the 3rd PEP-CMV vaccine on the last enrolled patient | |
Secondary | Mean or median change from baseline at each follow-up assessment in ELISPOT (IFN-?) | Quantitate the immune response to the components of the PEP-CMV vaccine by ELISPOT | 24 months | |
Secondary | Mean or median change from baseline at each follow-up assessment in ELISA (gB-KLH) | Quantitate the immune response to the components of the PEP-CMV vaccine by ELISA | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Completed |
NCT00953121 -
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
|
Phase 2 | |
Completed |
NCT00766467 -
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
|
Phase 2 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
Completed |
NCT02507583 -
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT04109209 -
Psychological Intervention For Brain Tumor Caregivers
|
N/A | |
Recruiting |
NCT04937413 -
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
|
Early Phase 1 | |
Completed |
NCT03615404 -
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
|
Phase 1 | |
Active, not recruiting |
NCT04175301 -
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
|
Phase 2 | |
Terminated |
NCT02659800 -
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02323880 -
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
|
Phase 1 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02861222 -
Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma
|
Phase 1 | |
Completed |
NCT00634231 -
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT01792505 -
Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT00190723 -
A Study of LY317615 in Patients With Brain Tumors
|
Phase 2 | |
Recruiting |
NCT04323046 -
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
|
Phase 1 |